4 articles in this category.
Beyond Wegovy and Zepbound, a new generation of obesity drugs is racing toward FDA approval. CagriSema, MariTide (monthly injection), survodutide, and more — here's every drug in the pipeline with clinical data.
The FDA just approved Eli Lilly's Foundayo (orforglipron) — the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.
Retatrutide achieved 28.7% weight loss in Phase 3 trials — nearly double semaglutide. Here's everything known about Eli Lilly's next-generation triple-agonist, from clinical data to expected approval timeline.
Medicare will begin covering GLP-1 weight loss medications at $50/month starting July 2026. Here's who qualifies, how it works, and what comes next.